Wyeth Pharmaceuticals (a Wyeth division) has entered into an Amended and Restated Co-Promotion Agreement regarding King's product ALTACE® (ramipril).
ALTACE® is angiotensin converting enzyme (ACE) inhibitor which King Pharmaceuticals will assume full responsibility for the selling and marketing of, starting January 1, 2007. But for the remainder of 2006, the Wyeth sales force will continue to promote the product with King.
Read the full press release at Wyeth or at King Pharma."Through this successful collaboration, ALTACE, King's flagship cardiovascular product, has grown into the leading branded ACE inhibitor, with net sales increasing from $122 million in 1999 to $554 million in 2005," stated Brian A. Markison, King's President and Chief Executive Officer.
"King was a much different company when it originally entered into the co-promotion arrangement, with approximately 200 sales representatives in June 2000. Today, our selling platform is more than 1,000 individuals strong, with deep and experienced coverage in primary care."
Comment Preview